Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

USPSTF: Screening for Prostate Cancer

JAMA; 2018 May 8; Grossman, et al

Clinicians should not screen men aged 55 to 69 years for prostate cancer who do not express a preference for screening, according to a new recommendation statement from the US Preventive Services Task Force (USPSTF). The statement, which updates the 2012 USPSTF recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer, also recommends against PSA-based screening for prostate cancer in men aged ≥70 years. The recommendation states:

  • For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)–based screening for prostate cancer should be an individual one.
  • Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision.
  • Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction.
  • In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes.
  • Clinicians should not screen men who do not express a preference for screening.
  • The USPSTF recommends against PSA-screening for prostate cancer in men aged ≥70 years.

Citation:

Grossman DC, USPSTF Task Force. Screening for Prostate Cancer. US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901-1913. doi:10.1001/jama.2018.3710.

This Week's Must Reads

Treating Low-Risk Patients with Mild Hypertension, JAMA Intern Med; ePub 2018 Oct 29; Sheppard, et al

Short Interpregnancy Intervals & Pregnancy Outcomes, JAMA Intern Med; ePub 2018 Oct 29; Schummers, et al

Peer Support Impact in Adults with T2D & Depression, Diabetes Care; ePub 2018 Oct 29; Cherrington, et al

Efficacy of Bariatric Procedures for Weight Loss, Ann Intern Med; ePub 2018 Oct 30; Arterburn, et al

Concomitant DOAC-Antiplatelet Use & Bleeding Risk, Am J Med; ePub 2018 Oct 25; Douros, et al

Must Reads in Clinical Guidelines

Screening for Syphilis Infection in Pregnant Women, JAMA; 2018 Sep 4; US Preventive Services Task Force

Treatment Intensification Guidelines for T2D , Ann Intern Med; ePub 2018 Sep 4; Roglic, et al

Low-Calorie Sweetened Beverages & Cardiometabolic Health, Circulation; ePub 2018 Jul 30; Johnson, et al

Antiretroviral Drugs for Management of HIV, JAMA; 2018 Jul 24/31; Saag, Benson, et al

ACC/AHA Guideline Impact on Prevalence of Hypertension, BMJ; ePub 2018 Jul 11; Khera, Lu, et al